Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvain Ladoire

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Frontiers in Immunology|August 22, 2024
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, <i>KEAP1/STK11</i> co-mutated metastatic NSCLCNicolas Roussot, Marion Thibaudin, Jean-David Fumet, et al.
European Urology|June 4, 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZAEmeline Colomba, Sarah Flora Jonas, Jean-Christophe Eymard, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.
Ebiomedicine|January 11, 2020
Implementation and use of whole exome sequencing for metastatic solid cancerManon Réda, Corentin Richard, Aurelie Bertaut, et al.
JAMA Oncology|November 5, 2020
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical TrialFrançois-Clément Bidard, William Jacot, Nicolas Kiavue, et al.
British Journal of Cancer|June 26, 2019
Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapyJean-David Fumet, Corentin Richard, Fanny Ledys, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
British Journal of Cancer|October 16, 2018
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapyJean-David Fumet, Corentin Richard, Fanny Ledys, et al.
Breast (Edinburgh, Scotland)|December 11, 2020
Impact of body mass index on overall survival in patients with metastatic breast cancerKhalil Saleh, Matthieu Carton, Véronique Dieras, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Frontiers in Immunology|August 22, 2024
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, <i>KEAP1/STK11</i> co-mutated metastatic NSCLCNicolas Roussot, Marion Thibaudin, Jean-David Fumet, et al.
European Urology|June 4, 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZAEmeline Colomba, Sarah Flora Jonas, Jean-Christophe Eymard, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.
Ebiomedicine|January 11, 2020
Implementation and use of whole exome sequencing for metastatic solid cancerManon Réda, Corentin Richard, Aurelie Bertaut, et al.
JAMA Oncology|November 5, 2020
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical TrialFrançois-Clément Bidard, William Jacot, Nicolas Kiavue, et al.
British Journal of Cancer|June 26, 2019
Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapyJean-David Fumet, Corentin Richard, Fanny Ledys, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
British Journal of Cancer|October 16, 2018
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapyJean-David Fumet, Corentin Richard, Fanny Ledys, et al.
Breast (Edinburgh, Scotland)|December 11, 2020
Impact of body mass index on overall survival in patients with metastatic breast cancerKhalil Saleh, Matthieu Carton, Véronique Dieras, et al.
Pageof 17